drugset / Trial / NCT01103414

Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients

NCT01103414

Phase 2 Completed 356 enrolled Metabolic Solutions Development Company
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability and efficacy of three dose levels of Mitoglitazone™ (MSDC-0160) in patients with type 2 diabetes.

Timeline

Start
2010-09
Primary completion
2011-11
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Mitoglitazone Small molecule 50 mg
Subject Mitoglitazone Small molecule 100 mg
Subject Mitoglitazone Small molecule 150 mg
Comparator Pioglitazone Small molecule 45 mg